SGFG
TARS icon

Silver Grove Financial Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Silver Grove Financial Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63 Buy
+1
New +$64 ﹤0.01% 2383

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Silver Grove Financial Group's TARS Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 1 share worth $63. The stake represents ﹤0.01% of the portfolio and ranks #2383 among its holdings.

257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Silver Grove Financial Group held 1 share of Tarsus Pharmaceuticals worth $63 as of Q2 2026.
  • Tarsus Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2383 holding.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.